Mesa Laboratories (NASDAQ:MLAB) CAO Lyndsey Elizabeth Crennen Sells 118 Shares of Stock

Mesa Laboratories, Inc. (NASDAQ:MLAB) CAO Lyndsey Elizabeth Crennen sold 118 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was sold at an average price of $101.27, for a total value of $11,949.86. Following the sale, the chief accounting officer owned 1,473 shares of the company’s stock, valued at $149,170.71. This represents a 7.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Mesa Laboratories Stock Performance

Shares of NASDAQ:MLAB opened at $94.95 on Thursday. The firm has a market capitalization of $524.12 million, a PE ratio of 79.13 and a beta of 0.94. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.72 and a quick ratio of 1.29. The business has a 50-day moving average of $101.90 and a two-hundred day moving average of $90.64. Mesa Laboratories, Inc. has a 12 month low of $55.45 and a 12 month high of $113.99.

Mesa Laboratories (NASDAQ:MLAB) last announced its quarterly earnings results on Wednesday, May 27th. The medical instruments supplier reported $1.53 EPS for the quarter, missing the consensus estimate of $1.78 by ($0.25). The firm had revenue of $63.72 million for the quarter, compared to analyst estimates of $65.21 million. Mesa Laboratories had a return on equity of 20.96% and a net margin of 2.69%.During the same quarter in the prior year, the company earned ($1.31) earnings per share.

Mesa Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, June 15th. Shareholders of record on Friday, May 29th were paid a dividend of $0.16 per share. The ex-dividend date was Friday, May 29th. This represents a $0.64 annualized dividend and a yield of 0.7%. Mesa Laboratories’s dividend payout ratio is currently 53.33%.

Institutional Investors Weigh In On Mesa Laboratories

A number of large investors have recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Mesa Laboratories by 4.9% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 3,068 shares of the medical instruments supplier’s stock valued at $364,000 after buying an additional 143 shares in the last quarter. American Century Companies Inc. grew its stake in shares of Mesa Laboratories by 1.5% in the second quarter. American Century Companies Inc. now owns 13,431 shares of the medical instruments supplier’s stock valued at $1,265,000 after buying an additional 194 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Mesa Laboratories by 30.9% in the third quarter. BNP Paribas Financial Markets now owns 1,029 shares of the medical instruments supplier’s stock valued at $69,000 after buying an additional 243 shares in the last quarter. Deutsche Bank AG grew its stake in Mesa Laboratories by 5.9% during the 4th quarter. Deutsche Bank AG now owns 4,440 shares of the medical instruments supplier’s stock valued at $349,000 after purchasing an additional 248 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. grew its stake in Mesa Laboratories by 5,366.7% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 328 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 322 shares in the last quarter. Institutional investors and hedge funds own 90.60% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings lowered Mesa Laboratories from a “sell (d+)” rating to a “sell (d)” rating in a research note on Wednesday, June 3rd. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $94.00.

About Mesa Laboratories

Mesa Laboratories, Inc (NASDAQ: MLAB) is a global provider of instrumentation products designed for critical process monitoring, testing and calibration. Headquartered in Lakewood, Colorado, the company serves a diverse set of end markets including healthcare, pharmaceutical, food and beverage, energy and industrial sectors. With a focus on precision measurement and validation, Mesa Laboratories helps customers ensure regulatory compliance, product safety and operational efficiency across complex manufacturing and sterilization processes.

The company’s product portfolio encompasses biological and chemical indicators for sterilization process validation, digital data loggers and sensors for environmental monitoring, and optical gas analyzers with sample-conditioning solutions for oil, gas and petrochemical applications.